Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
Conditions
Interventions
- BIOLOGICAL: Sotrovimab (Gen1)
- BIOLOGICAL: Sotrovimab (Gen2)
- BIOLOGICAL: Sotrovimab (Gen2)
Sponsor
Vir Biotechnology, Inc.
Collaborators